» Articles » PMID: 21958592

Empirical Derivation of the Reference Region for Computing Diagnostic Sensitive ¹⁸fluorodeoxyglucose Ratios in Alzheimer's Disease Based on the ADNI Sample

Overview
Specialties Biochemistry
Biophysics
Date 2011 Oct 1
PMID 21958592
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Careful selection of the reference region for non-quantitative positron emission tomography (PET) analyses is critically important for Region of Interest (ROI) data analyses. We introduce an empirical method of deriving the most suitable reference region for computing neurodegeneration sensitive (18)fluorodeoxyglucose (FDG) PET ratios based on the dataset collected by the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. Candidate reference regions are selected based on a heat map of the difference in coefficients of variation (COVs) of FDG ratios over time for each of the Automatic Anatomical Labeling (AAL) atlas regions normalized by all other AAL regions. Visual inspection of the heat map suggests that the portion of the cerebellum and vermis superior to the horizontal fissure is the most sensitive reference region. Analyses of FDG ratio data show increases in significance on the order of ten-fold when using the superior portion of the cerebellum as compared with the traditionally used full cerebellum. The approach to reference region selection in this paper can be generalized to other radiopharmaceuticals and radioligands as well as to other disorders where brain changes over time are hypothesized and longitudinal data is available. Based on the empirical evidence presented in this study, we demonstrate the usefulness of the COV heat map method and conclude that intensity normalization based on the superior portion of the cerebellum may be most sensitive to measuring change when performing longitudinal analyses of FDG-PET ratios as well as group comparisons in Alzheimer's disease. This article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.

Citing Articles

The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.

Cacciaglia R, Shekari M, Salvado G, Mila-Aloma M, Falcon C, Sanchez-Benavides G Brain Commun. 2024; 7(1):fcae451.

PMID: 39723106 PMC: 11668178. DOI: 10.1093/braincomms/fcae451.


Neuroimaging statistical approaches for determining neural correlates of Alzheimer's disease via positron emission tomography imaging.

Drake D, Derado G, Zhang L, Bowman F Wiley Interdiscip Rev Comput Stat. 2024; 15(5).

PMID: 39655245 PMC: 11626230. DOI: 10.1002/wics.1606.


Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum.

Salvado G, Mila-Aloma M, Shekari M, Ashton N, Operto G, Falcon C Eur J Nucl Med Mol Imaging. 2022; 49(13):4567-4579.

PMID: 35849149 PMC: 9606048. DOI: 10.1007/s00259-022-05897-4.


Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.

Salvado G, Shekari M, Falcon C, Operto G, Mila-Aloma M, Sanchez-Benavides G Brain Commun. 2022; 4(3):fcac134.

PMID: 35702732 PMC: 9185381. DOI: 10.1093/braincomms/fcac134.


Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device.

Epelbaum S, Burgos N, Canney M, Matthews D, Houot M, Santin M Alzheimers Res Ther. 2022; 14(1):40.

PMID: 35260178 PMC: 8905724. DOI: 10.1186/s13195-022-00981-1.


References
1.
Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

2.
Berg L . Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988; 24(4):637-9. View

3.
Walhovd K, Fjell A, Dale A, McEvoy L, Brewer J, Karow D . Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol Aging. 2008; 31(7):1107-21. PMC: 3947581. DOI: 10.1016/j.neurobiolaging.2008.08.013. View

4.
Walhovd K, Fjell A, Brewer J, McEvoy L, Fennema-Notestine C, Hagler Jr D . Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol. 2010; 31(2):347-54. PMC: 2821467. DOI: 10.3174/ajnr.A1809. View

5.
Minoshima S, Frey K, Foster N, Kuhl D . Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995; 19(4):541-7. DOI: 10.1097/00004728-199507000-00006. View